WCMNY
NKGN

Westchester Capital Management (New York)’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Westchester Capital Management (New York)’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-105,266
Closed -$1.09M – 296
2023
Q3 		$1.09M Hold
105,266
– – 0.03% 212
2023
Q2 		$1.09M Buy
+105,266
New +$1.08M 0.03% 224

Other funds holding NKGN

SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 13.88% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Westchester Capital Management (New York)'s NKGN Position: Q4 2023 in Review

Westchester Capital Management (New York) sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 105,266 shares — an estimated $1.09M sold.

Westchester Capital Management (New York) first reported a position in NKGN in Q2 2023 and held it in 2 quarters. The position peaked at $1.09M in Q3 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

  • Westchester Capital Management (New York) reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 105,266 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $1.09M.
  • Westchester Capital Management (New York) first reported a position in NKGen Biotech, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Westchester Capital Management (New York)'s NKGen Biotech, Inc. Common Stock position peaked at $1.09M in Q3 2023.
  • 9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2023, filed 15 Feb 2024.